Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

Cisplatin 274pembrolizumab 229Radiotherapy 166Cetuximab 163Carboplatin 122Docetaxel 109Paclitaxel 94Fluorouracil 94Nivolumab 84Radiotherapy, Intensity-Modulated 78Magnetic Resonance Spectroscopy 39durvalumab 35Radiation 32Surgical Procedures, Operative 31Drug Therapy 30Radiosurgery 25Erlotinib Hydrochloride 25Biopsy 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Platinum 22Specimen Handling 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Capecitabine 19tremelimumab 18Ipilimumab 18Gemcitabine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Cell Carcinoma of Head and Neck × yeast-CEA vaccine × Clear all
NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡